Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update
From MarketBeat:
Aquestive Therapeutics, Inc. experienced a significant rise in short interest in December, with short interest reaching a total of 2,070,000 shares as of December 15th. This represents a growth of 10.1% from the previous month’s total of 1,880,000 shares. The short-interest ratio is currently 6.1 days based on an average daily volume of 341,100 shares. Several analysts have offered ratings and price targets for Aquestive Therapeutics. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective, while Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price. Additionally, HC Wainwright increased the target price to $6.00 and gave the company a “buy” rating. A number of institutional investors have increased their stakes in Aquestive Therapeutics, with Armistice Capital LLC leading the way with a 314.5% increase in its stake. The company now has institutional ownership of 30.91%. Aquestive Therapeutics opened at $2.02 on Tuesday, with a market cap of $134.88 million and a P/E ratio of -8.08. The stock’s fifty-day moving average price is $1.88, and its two-hundred-day moving average price is $1.76. Aquestive Therapeutics recently released its quarterly earnings results, reporting ($0.03) earnings per share, which surpassed the consensus estimate of ($0.11) by $0.08. The company delivered revenue of $13.00 million during the quarter, surpassing the consensus estimate of $11.33 million. Aquestive Therapeutics has a 1 year low of $0.72 and a 1 year high of $2.69. Aquestive Therapeutics, Inc. is a pharmaceutical company that focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets several products, including Sympazan, Suboxone, Zuplenz, and Azstarys.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting.
Read more: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update